Newsroom

ICYMI: National Journal article features CSRxP’s White Paper

This morning, the National Journal published an article regarding an increase in public concern over the high cost of prescription drugs. The article references CSRxP’s white paper, “Specialty Drug Hyperinflation: The Risk to Patients and the Health Care System.”

Read more

Vertex’s Kalydeco combo could run payers $10M-plus per life, PBM figures

Sky-high drug prices have been causing their fair share of consternation among payers lately, and industry watchers have suspected for a while now that Vertex ($VRTX) will stir the pot when its new cystic fibrosis combo–expected to win FDA approval later this year–hits the market. But just how much will payers need to shell out for the new med over time? Prime Therapeutics has some ideas.

Read more

Congressional Briefing Resources

April 09, 2015 Congressional Briefing Resources   Peter Bach, MD, MAPP Director, Memorial Sloan Kettering’s Center for Health Policy and Outcomes The systemwide impact of new cancer […]

Read more

The Impact of Rising Drug Costs on Patients, Providers and Public Programs

The Campaign for Sustainable Rx Pricing (CSRxP), a project of the National Coalition on Health Care, is hosting a Congressional briefing on Thursday, April 9.

Read more